Statements (59)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:bfsLayer |
5
|
| gptkbp:bfsParent |
gptkb:Buprenorphine
gptkb:North_Carolina_Opioid_Crisis_Response_Act |
| gptkbp:activities |
opioid receptor antagonist
|
| gptkbp:advocates_for |
increased access to naloxone
|
| gptkbp:appointed_by |
intramuscular injection
intravenous injection intranasal spray |
| gptkbp:approves |
gptkb:1971
gptkb:FDA |
| gptkbp:associated_with |
opioid crisis
reversal of respiratory depression reversal of sedation |
| gptkbp:availability |
over-the-counter in some regions
|
| gptkbp:brand |
gptkb:Zimhi
Kloxxado |
| gptkbp:clinical_trial |
studies on safety
studies on effectiveness studies on administration routes |
| gptkbp:contraindication |
hypersensitivity to naloxone
|
| gptkbp:developed_by |
gptkb:Eli_Lilly_and_Company
|
| gptkbp:formulation |
gptkb:fragrance
injectable solution |
| https://www.w3.org/2000/01/rdf-schema#label |
naloxone
|
| gptkbp:impact |
public health
reduces opioid overdose deaths |
| gptkbp:influenced_by |
public health policies
|
| gptkbp:influences |
drug policy reform
|
| gptkbp:is_available_on |
generic drug
|
| gptkbp:is_effective_against |
non-opioid overdoses
alcohol overdose benzodiazepine overdose |
| gptkbp:is_used_by |
first responders
bystanders in emergencies |
| gptkbp:is_used_for |
opioid overdose
|
| gptkbp:legal_issue |
prescription medication
|
| gptkbp:manager |
intravenous
intranasal intramuscular |
| gptkbp:part_of |
emergency kits
opioid overdose response |
| gptkbp:public_awareness |
aim to educate about naloxone
|
| gptkbp:shelf_life |
24 months
|
| gptkbp:side_effect |
nausea
vomiting withdrawal symptoms high blood pressure increased heart rate |
| gptkbp:storage |
room temperature
|
| gptkbp:suitable_for |
gptkb:CDC
gptkb:WHO |
| gptkbp:traded_on |
gptkb:Narcan
|
| gptkbp:training |
community organizations
healthcare providers for administration |
| gptkbp:used_in |
emergency medicine
substance use disorder treatment harm reduction programs |